Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Table 3 AEs in patients with EGFR Mut + NSCLC treated with gefitinib (≥ 2% of patients)

	n (N = 222)	%
All	129	58.1
Dermatology/skin
Rash: acne/acneiform	53	23.9
Dry skin	24	10.8
Nail changes	14	6.3
Pruritus/itching	14	6.3
Dermatology/skin – other	11	5.0
Hair loss/alopecia	9	4.1
Rash/desquamation	8	3.6
Gastrointestinal
Diarrhea	40	18.0
Nausea	17	7.7
Vomiting	8	3.6
Cardiac general
Cardiac ischemia/infarction	5	2.3
Constitutional symptoms
Constitutional symptoms – other	6	2.7
Fatigue (asthenia, lethargy, malaise)	5	2.3
Ocular/visual
Other	6	2.7
Hemorrhage/bleeding
Hemorrhage, pulmonary/upper respiratory – nose	5	2.3
Neurology
Neuropathy: sensory	5	2.3
Pulmonary/upper respiratory
Dyspnea (shortness of breath)	5	2.3
Renal/genitourinary
Cystitis^a	4	1.8

Adverse events by CTC symptoms related to gefitinib and serious adverse events related and not related to gefitinib. AE, adverse event; CTC, Common Toxicity Criteria; NSCLC, non-small-cell lung cancer. ^aIncludes one patient in whom cystitis was not related to gefitinib and was not serious

ISSN: 1471-2407